Quick Answer
Glucotrack, Inc. reported Total Revenue of $208.0 thousand for fiscal year 2019.
Glucotrack, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — | — |
| Revenue (ASC 606) | — | — | — | — | — | — |
| Net Income | -$19.39M +14.2% |
-$22.60M -218.4% |
-$7.10M -60.0% |
-$4.43M -9.0% |
-$4.07M -50.9% |
-$2.70M -176.7% |
| Diluted EPS | $31.22 -99.2% |
$4106.00 +11912.9% |
$34.18 +11686.2% |
$0.29 +11.5% |
$0.26 +36.8% |
$0.19 +1050.0% |
| Total Assets | $7.84M +32.1% |
$5.93M +20.9% |
$4.91M +101.2% |
$2.44M -61.1% |
$6.26M -40.9% |
$10.61M +867.7% |
| Cash and Equivalents | $7.38M +31.4% |
$5.62M +25.0% |
$4.49M +94.3% |
$2.31M -61.9% |
$6.06M -38.3% |
$9.82M +2244.4% |
| Stockholders Equity | $2.83M +121.8% |
-$13.00M -506.6% |
$3.20M +159.9% |
$1.23M -76.1% |
$5.16M -42.6% |
$8.98M +736.1% |
| R&D Expense | $9.81M +3.3% |
$9.50M +101.9% |
$4.70M +139.1% |
$1.97M +8.7% |
$1.81M +18.1% |
$1.53M -4.6% |
| Operating Income | -$16.09M -10.6% |
-$14.55M -104.8% |
-$7.10M -60.3% |
-$4.43M -9.7% |
-$4.04M -29.0% |
-$3.13M -189.3% |
| Shares Outstanding | 910,688 +6691.6% |
13,409 -93.6% |
208,914 -98.7% |
15.50M +0.2% |
15.47M +0.2% |
15.44M -90.5% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | June 30, 2020 | $97.00 | -99.9% | -95.5% |
| Revenue (ASC 606) | June 30, 2020 | $97.00 | -99.9% | -95.5% |
| Net Income | September 30, 2025 | -$4.17M | +18.0% | +12.3% |
| Diluted EPS | September 30, 2025 | $4.64 | -99.6% | -51.8% |
| Total Assets | September 30, 2025 | $8.29M | +903.6% | -18.8% |
| Cash and Equivalents | September 30, 2025 | $7.87M | +2174.3% | -17.6% |
| Stockholders Equity | September 30, 2025 | $2.75M | +168.4% | -60.0% |
| R&D Expense | September 30, 2025 | $3.17M | +53.4% | +0.5% |
| Operating Income | September 30, 2025 | -$4.31M | -32.5% | +10.2% |
| Shares Outstanding | September 30, 2025 | 899,410 | -84.4% | +0.0% |
- Glucotrack, Inc. reported Total Revenue of $208.0 thousand for fiscal year 2019.
- Glucotrack, Inc. showed an increase of +378.3% in Total Revenue compared to the prior fiscal year.
- Glucotrack, Inc. reported Revenue (ASC 606) of $208.0 thousand for fiscal year 2019.
- Glucotrack, Inc. showed an increase of +378.3% in Revenue (ASC 606) compared to the prior fiscal year.
- Glucotrack, Inc. reported Net Income of -$19.39 million for fiscal year 2025.
- Glucotrack, Inc. showed an increase of +14.2% in Net Income compared to the prior fiscal year.
- Glucotrack, Inc. reported Diluted EPS of $31.22 per share for fiscal year 2025.
- Glucotrack, Inc. showed a decrease of -99.2% in Diluted EPS compared to the prior fiscal year.
- Glucotrack, Inc. reported Total Assets of $7.84 million for fiscal year 2025.
- Glucotrack, Inc. showed an increase of +32.1% in Total Assets compared to the prior fiscal year.
- Glucotrack, Inc. reported Cash and Equivalents of $7.38 million for fiscal year 2025.
- Glucotrack, Inc. showed an increase of +31.4% in Cash and Equivalents compared to the prior fiscal year.
- Glucotrack, Inc. reported Stockholders Equity of $2.83 million for fiscal year 2025.
- Glucotrack, Inc. showed an increase of +121.8% in Stockholders Equity compared to the prior fiscal year.
- Glucotrack, Inc. reported R&D Expense of $9.81 million for fiscal year 2025.
- Glucotrack, Inc. showed an increase of +3.3% in R&D Expense compared to the prior fiscal year.
- Glucotrack, Inc. reported Operating Income of -$16.09 million for fiscal year 2025.
- Glucotrack, Inc. showed a decrease of -10.6% in Operating Income compared to the prior fiscal year.
- Glucotrack, Inc. reported Shares Outstanding of 910.7 thousand shares for fiscal year 2025.
- Glucotrack, Inc. showed an increase of +6691.6% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: